Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ACLY_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ACLY_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ACLY_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ACLY_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ACLY_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ACLY_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060844 | Skin | cSCC | acetyl-CoA metabolic process | 16/4864 | 35/18723 | 9.09e-03 | 4.16e-02 | 16 |
GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
GO:000915028 | Thyroid | PTC | purine ribonucleotide metabolic process | 165/5968 | 368/18723 | 1.03e-07 | 2.05e-06 | 165 |
GO:007252127 | Thyroid | PTC | purine-containing compound metabolic process | 182/5968 | 416/18723 | 1.92e-07 | 3.51e-06 | 182 |
GO:000925927 | Thyroid | PTC | ribonucleotide metabolic process | 170/5968 | 385/18723 | 2.32e-07 | 4.08e-06 | 170 |
GO:000616327 | Thyroid | PTC | purine nucleotide metabolic process | 170/5968 | 396/18723 | 2.02e-06 | 2.75e-05 | 170 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
GO:000915224 | Thyroid | PTC | purine ribonucleotide biosynthetic process | 78/5968 | 169/18723 | 6.88e-05 | 6.01e-04 | 78 |
GO:004639024 | Thyroid | PTC | ribose phosphate biosynthetic process | 85/5968 | 190/18723 | 1.30e-04 | 1.03e-03 | 85 |
GO:000926024 | Thyroid | PTC | ribonucleotide biosynthetic process | 81/5968 | 182/18723 | 2.27e-04 | 1.65e-03 | 81 |
GO:00723505 | Thyroid | PTC | tricarboxylic acid metabolic process | 11/5968 | 14/18723 | 4.45e-04 | 2.95e-03 | 11 |
GO:007252219 | Thyroid | PTC | purine-containing compound biosynthetic process | 86/5968 | 200/18723 | 5.85e-04 | 3.72e-03 | 86 |
GO:000616419 | Thyroid | PTC | purine nucleotide biosynthetic process | 81/5968 | 191/18723 | 1.35e-03 | 7.65e-03 | 81 |
GO:00442726 | Thyroid | PTC | sulfur compound biosynthetic process | 63/5968 | 148/18723 | 3.91e-03 | 1.87e-02 | 63 |
GO:001969328 | Thyroid | ATC | ribose phosphate metabolic process | 184/6293 | 396/18723 | 5.87e-08 | 1.05e-06 | 184 |
GO:000915029 | Thyroid | ATC | purine ribonucleotide metabolic process | 172/6293 | 368/18723 | 9.58e-08 | 1.64e-06 | 172 |
GO:000925928 | Thyroid | ATC | ribonucleotide metabolic process | 178/6293 | 385/18723 | 1.47e-07 | 2.39e-06 | 178 |
GO:007252128 | Thyroid | ATC | purine-containing compound metabolic process | 189/6293 | 416/18723 | 2.83e-07 | 4.29e-06 | 189 |
GO:0006753111 | Thyroid | ATC | nucleoside phosphate metabolic process | 219/6293 | 497/18723 | 5.92e-07 | 8.29e-06 | 219 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACLY | SNV | Missense_Mutation | | c.2996C>T | p.Pro999Leu | p.P999L | P53396 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-A2-A0SU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ACLY | SNV | Missense_Mutation | | c.2543G>A | p.Arg848Gln | p.R848Q | P53396 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
ACLY | SNV | Missense_Mutation | novel | c.1285N>A | p.Pro429Thr | p.P429T | P53396 | protein_coding | tolerated(0.12) | benign(0.399) | TCGA-A7-A4SB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | CR |
ACLY | SNV | Missense_Mutation | novel | c.2798A>G | p.Asp933Gly | p.D933G | P53396 | protein_coding | deleterious(0.04) | possibly_damaging(0.735) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACLY | SNV | Missense_Mutation | | c.604N>T | p.Ile202Phe | p.I202F | P53396 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ACLY | insertion | Frame_Shift_Ins | novel | c.1181_1182insGGCAGCGAGA | p.Gly395AlafsTer67 | p.G395Afs*67 | P53396 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ACLY | SNV | Missense_Mutation | | c.22N>C | p.Glu8Gln | p.E8Q | P53396 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ACLY | SNV | Missense_Mutation | novel | c.940C>A | p.Gln314Lys | p.Q314K | P53396 | protein_coding | tolerated(0.85) | benign(0.007) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ACLY | SNV | Missense_Mutation | rs782078720 | c.1384N>A | p.Asp462Asn | p.D462N | P53396 | protein_coding | tolerated(0.52) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
ACLY | SNV | Missense_Mutation | rs387907386 | c.1484N>A | p.Arg495His | p.R495H | P53396 | protein_coding | tolerated(0.07) | benign(0.3) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |